Glaucoma – Current Treatment – Detailed, Expanded Analysis (US)

Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to lower and stabilize IOP. Pharmacotherapy is widely used, and nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease, primary open-angle glaucoma (OAG). Although the U.S. glaucoma therapy market is crowded and highly genericized, branded therapies play an important role, particularly in later lines of therapy. Recent-to-market therapies—Alcon’s Rocklatan and AbbVie’s Durysta—have expanded the treatment armamentarium for OAG. Among nonpharmacological approaches, incisional glaucoma surgery, laser trabeculoplasty, and developments in devices for micro / minimally invasive glaucoma surgery (MIGS) offer additional advances to manage OAG patients.

Questions answered

  • What key differences exist in primary OAG treatment between ophthalmologists and optometrists in the United States?
  • How are more recently launched therapies such as AbbVie’s Durysta and Bausch + Lomb’s Vyzulta faring in later lines of therapies?
  • How successful is Alcon’s newer once-daily fixed-dose combination (FDC), Rocklatan, compared with other FDCs such as twice-daily AbbVie’s Combigan, Thea’s Cosopt, or Alcon’s thrice-daily Simbrinza?
  • How compelling has Sun Ophthalmics’s Xelpros, a BAK-free formulation of latanoprost, proven compared with Pfizer’s Xalatan or generic versions of latanoprost?
  • Which MIGS devices garner the greatest share among primary OAG patients, and does device preference vary between ophthalmologists and optometrists?
  • Have data from the LiGHT trial on the use of selective laser trabeculoplasty in early lines of therapy influenced physicians’ use of this approach?
  • How do ophthalmologists and optometrists envision their treatment of primary OAG to evolve over the next three years?

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets Covered: United States.

Primary research: Survey of 85 U.S. ophthalmologists and 20 optometrists.

Key drugs covered: Durysta, Vyzulta, Xelpros, Rhopressa, Rocklatan, Combigan, and Simbrinza.

Key companies: Alcon, AbbVie, Sun Ophthalmics, and Bausch + Lomb

Key insights provided

  • Factors influencing disease management and treatment decisions.
  • Drivers and constraints of treatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight on persistency and compliance.
  • Physician-reported recent / anticipated changes in brand usage over the next three years.

Table of contents

  • Glaucoma - Current Treatment - Detailed, Expanded Analysis (US)
    • Glaucoma | Current Treatment: Physician Insights | US | 2022 - Report

Login to access report